Charles Schwab Investment Management Inc. Has $2.84 Million Stock Position in Cryoport, Inc. (NASDAQ:CYRX)

Charles Schwab Investment Management Inc. cut its position in Cryoport, Inc. (NASDAQ:CYRX) by 5.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 365,095 shares of the company’s stock after selling 22,619 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.74% of Cryoport worth $2,840,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Intech Investment Management LLC acquired a new stake in shares of Cryoport in the third quarter valued at about $105,000. Algert Global LLC increased its holdings in shares of Cryoport by 282.7% during the 3rd quarter. Algert Global LLC now owns 247,483 shares of the company’s stock worth $2,007,000 after purchasing an additional 182,808 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in shares of Cryoport during the third quarter valued at about $82,000. Fred Alger Management LLC lifted its stake in shares of Cryoport by 49.9% in the third quarter. Fred Alger Management LLC now owns 2,698,768 shares of the company’s stock valued at $21,887,000 after buying an additional 898,481 shares during the period. Finally, Point72 Asset Management L.P. acquired a new stake in Cryoport during the third quarter worth about $3,405,000. Institutional investors own 92.90% of the company’s stock.

Insider Activity

In related news, CEO Jerrell Shelton sold 4,620 shares of the firm’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $6.29, for a total value of $29,059.80. Following the transaction, the chief executive officer now owns 765,399 shares in the company, valued at $4,814,359.71. This trade represents a 0.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 19,830 shares of company stock valued at $118,353 over the last three months. 10.10% of the stock is owned by insiders.

Cryoport Stock Up 0.3 %

Shares of CYRX opened at $6.24 on Friday. The company has a market capitalization of $311.44 million, a P/E ratio of -1.85 and a beta of 1.67. Cryoport, Inc. has a one year low of $4.58 and a one year high of $20.11. The business’s 50 day simple moving average is $6.71 and its 200-day simple moving average is $7.33. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.70 and a quick ratio of 5.32.

Cryoport (NASDAQ:CYRX) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.09). Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. The business had revenue of $59.53 million during the quarter, compared to analyst estimates of $58.71 million. During the same period in the prior year, the firm posted ($0.29) EPS. As a group, sell-side analysts predict that Cryoport, Inc. will post -0.99 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price target on shares of Cryoport in a report on Wednesday, March 5th. Guggenheim started coverage on shares of Cryoport in a research note on Thursday, December 19th. They issued a “buy” rating and a $11.00 target price on the stock. Finally, UBS Group upgraded shares of Cryoport from a “neutral” rating to a “buy” rating and set a $10.00 price target for the company in a research note on Monday. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, Cryoport currently has an average rating of “Moderate Buy” and an average target price of $11.67.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.